Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676184 | 0.89 | POLB (0.49) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL6673833 | 0.81 | RARA (0.53) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL6674449 | 0.78 | MEN1 (0.55) | MEN1KMT2ANPC1RAB9ACYP3A4 | |
| SCHEMBL10941351 | 0.74 | ALDH1A1 (0.68) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL7152414 | 0.73 | RARA (0.51) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL1483661 | 0.73 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL11735134 | 0.73 | MEN1 (0.66) | MEN1KMT2AMAPTNPC1MAPK1 | |
| SCHEMBL30810715 | 0.72 | CASP6 (0.72) | TSHRLMNAPOLB | |
| SCHEMBL145092 | 0.72 | CASP6 (0.72) | TSHRLMNAPOLB | |
| SCHEMBL842661 | 0.72 | CASP6 (0.72) | TSHRLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0862555-B1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2004-10-20 | — | — | EP | claimed |
| US-20020091262-A1 | Substituted aryl or heteroarylamides having retinoid-like biological activity | ALLERGAN | 2002-07-11 | — | — | US | claimed |
| EP-0862555-A1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-09-09 | — | — | EP | claimed |
| US-5663357-A | COMPOUNDS FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-09-02 | — | — | US | claimed |
| WO-1997019062-A1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1997-05-29 | — | — | WO | claimed |
| EP-0862555-B1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6610744-B2 | Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition | ALLERGAN, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6534544-B1 | Administering retinoid compound as anticarcinogenic and antitumor agents; side effect reduction | ALLERGAN SALES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6437129-B1 | ARMOATIC OR HETEROARMOATIC COMPOUND CONTAINING SUBSTITUTED AMIDES OR THIOAMIDES | ALLERGAN SALES, LLC | 2002-08-20 | — | — | US | disclosed |
| US-20020091262-A1 | Substituted aryl or heteroarylamides having retinoid-like biological activity | ALLERGAN | 2002-07-11 | — | — | US | disclosed |
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | ALLERGAN SALES, INC. | 2002-06-20 | — | — | US | disclosed |
| US-6320047-B1 | ACYL- OR THIOACYL-AMINOPYRIDINES | ALLERGAN SALES, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6245786-B1 | ANTIPROLIFERATIVE AGENTS; SKIN DISORDERS | ALLERGAN SALES, INC. | 2001-06-12 | — | — | US | disclosed |
| US-6051713-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION, PARTICULARLY AS AGENTS FOR TREATING SKIN RELATED DISEASES, INCLUDING ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-KERATINIZATION SKIN DISORDERS | ALLERGAN SALES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5965606-A | RETINOID RECEPTORS, 2-FLUORO-4-(2',2',4',4'-TETRAMETHYL-8'-TRIFLUOROMETHYLCHROMAN-6' -YL)CARBAMOYL BENZOIC ACID FOR TREATING MONOCYTIC LEUKEMIA | ALLERGAN SALES, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5917048-A | Substituted aryl or heteroarylamides having retinoid-like biological activity | ALLERGAN SALES INC. (US) | 1999-06-29 | — | — | US | disclosed |
| US-5663357-A | COMPOUNDS FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | RARG, RARA, RARB | MEN1 1642/4885KMT2A 1165/4885ALDH1A1 391/4885 |
| US-20020091262-A1 | Substituted aryl or heteroarylamides having retinoid-like biological activity | CCR8, RXRA, CBR1 | MEN1 3794/4885KMT2A 2801/4885ALDH1A1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.